BioSpace News Archive

Bruker Announces SciY™ Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries.

Cybin Inc. is pleased to announce that Amir Inamdar, MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, will be participating in the upcoming PSYCH Symposium 2023 taking place Thursday, July 6, 2023 at the British Museum in London, UK.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of a study in JCO Precision Oncology1 in which DecisionDx®-Melanoma provided significant, independent risk stratification of patients with cutaneous melanoma (CM), beyond American Joint Committee on Cancer Eighth Edition (AJCC8) stage, which may help inform more personalized patient management decisions.

Ocugen, Inc. today announced that the Company’s Chairman, CEO and Co-Founder will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.

ProMIS Neurosciences Inc. is pleased to announce the Annual Meeting of Shareholders was held by virtual web-cast meeting, on Thursday, June 29, 2023 at 9:30 a.m.

AEON Biopharma, Inc. and Priveterra Acquisition Corp. (NASDAQ: PMGM) (“Priveterra”), a special purpose acquisition company, today announced that a total of up to $125 million in funding has been arranged in connection with the proposed business combination between AEON and Priveterra.

FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions.

PharmaEssentia Corporation today announced the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b (marketed as BESREMi ® ) for the treatment of patients with polycythemia vera (PV).

Cyteir Therapeutics, Inc. (“Cyteir” or the “Company”) (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor.

NLS Pharmaceutics Ltd. today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.